Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria

Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for...

Full description

Saved in:
Bibliographic Details
Published inTransplantation proceedings Vol. 43; no. 10; pp. 3813 - 3818
Main Authors Hanouneh, I.A, Macaron, C, Lopez, R, Aucejo, F, Zein, N.N
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier Inc 01.12.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC). Methods We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3 , where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed. Results Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7–30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P = .001), poorly differentiated tumors (HR 13; P = .039), the presence of microvascular invasion (HR 7.9; P = .001), higher TTV (HR 1.03; P < .001), and faster tumor growth (HR 1.09; P < .001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3 /mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth <1.61 cm3 /mo experienced less recurrence (11% vs 58%; P = .023) than those beyond the Milan criteria with tumor growth >1.61 cm3 /mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria. Conclusions Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome.
AbstractList It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC). We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3, where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed. Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7-30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P=.001), poorly differentiated tumors (HR 13; P=.039), the presence of microvascular invasion (HR 7.9; P=.001), higher TTV (HR 1.03; P<.001), and faster tumor growth (HR 1.09; P<.001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3/mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth<1.61 cm3/mo experienced less recurrence (11% vs 58%; P=.023) than those beyond the Milan criteria with tumor growth>1.61 cm3/mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria. Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome.
It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC). We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr 3, where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed. Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7–30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P = .001), poorly differentiated tumors (HR 13; P = .039), the presence of microvascular invasion (HR 7.9; P = .001), higher TTV (HR 1.03; P < .001), and faster tumor growth (HR 1.09; P < .001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm 3/mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth <1.61 cm 3/mo experienced less recurrence (11% vs 58%; P = .023) than those beyond the Milan criteria with tumor growth >1.61 cm 3/mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria. Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome.
BACKGROUNDIt is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC).METHODSWe identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3, where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed.RESULTSNinety-two patients were included in the study. The median follow-up was 19.5 (range 10.7-30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P=.001), poorly differentiated tumors (HR 13; P=.039), the presence of microvascular invasion (HR 7.9; P=.001), higher TTV (HR 1.03; P<.001), and faster tumor growth (HR 1.09; P<.001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3/mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth<1.61 cm3/mo experienced less recurrence (11% vs 58%; P=.023) than those beyond the Milan criteria with tumor growth>1.61 cm3/mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria.CONCLUSIONSPatients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome.
Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC). Methods We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3 , where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed. Results Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7–30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P = .001), poorly differentiated tumors (HR 13; P = .039), the presence of microvascular invasion (HR 7.9; P = .001), higher TTV (HR 1.03; P < .001), and faster tumor growth (HR 1.09; P < .001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3 /mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth <1.61 cm3 /mo experienced less recurrence (11% vs 58%; P = .023) than those beyond the Milan criteria with tumor growth >1.61 cm3 /mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria. Conclusions Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome.
Author Aucejo, F
Hanouneh, I.A
Macaron, C
Zein, N.N
Lopez, R
Author_xml – sequence: 1
  fullname: Hanouneh, I.A
– sequence: 2
  fullname: Macaron, C
– sequence: 3
  fullname: Lopez, R
– sequence: 4
  fullname: Aucejo, F
– sequence: 5
  fullname: Zein, N.N
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25344251$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22172852$$D View this record in MEDLINE/PubMed
BookMark eNqNUk1vEzEQtVARTQt_AVlIiFOCP5MsB6SypS1SEFWbni3HOyscNnawvUX5C_3VzDapQJy42GPNmzfj9-aEHIUYgJA3nE0449P360lJNuRtig6gmQjG-YRVE6bkMzLi85kci6mQR2TEmOJjLpU-Jic5rxm-hZIvyLEQfCbmWozIw40tQGNLl_0mJnqZ4q_ynV4naLwrmd6A61OC4B4xV7C1BZt2Xd_ZRGubnA9xY-lZWyDRhb_Hc_k4W2dDscXHQH2g1xhBQLpPsIuhoV89pim2u6tvL2idPFZ7-5I8b22X4dXhPiV3F5-X9dV48e3yS322GDs1VWUsW6lXSopGMzdX80brSvEZd8qttGWKNU5q7aZSOOfAVis5m7dN1bRTjAVDdU7Juz0vCvizh1zMxufhUzZA7LOpOK8040Ij8sMe6VLMOUFrtslvbNoZzsxghVmbv60wgxWGVQatwOLXhzb9aoO5p9In7RHw9gCw2dmuRSLn8x-clkoJzRF3vscBinLvIZns_GBJ4xO4Ypro_2-ej__QuM4Hj51_wA7yOvYpoOyGmywMM7fD8gy7w5EY94nJ39SfxlQ
CODEN TRPPA8
CitedBy_id crossref_primary_10_1007_s11901_012_0156_0
crossref_primary_10_1016_j_cld_2014_05_013
crossref_primary_10_1016_j_jvir_2014_09_012
crossref_primary_10_1016_j_iliver_2024_100077
crossref_primary_10_1016_j_jviscsurg_2017_12_001
crossref_primary_10_1097_MCG_0b013e318286ff8e
crossref_primary_10_1016_S1499_3872_15_60349_6
crossref_primary_10_3748_wjg_v22_i12_3325
crossref_primary_10_3892_etm_2017_4748
crossref_primary_10_1016_j_jchirv_2017_02_006
crossref_primary_10_1007_s11605_013_2140_6
crossref_primary_10_1016_j_surg_2016_08_049
crossref_primary_10_1016_j_transproceed_2014_10_044
crossref_primary_10_1136_gutjnl_2014_308483
crossref_primary_10_1093_bjsopen_zrab130
Cites_doi 10.1053/j.gastro.2007.04.061
10.1053/jlts.2002.34923
10.1016/j.transproceed.2010.10.012
10.1002/lt.21484
10.1097/01.TP.0000152801.82734.74
10.1053/jhep.2001.23561
10.1038/nm1377
10.1056/NEJM199903113401001
10.1002/hep.20933
10.1056/NEJMoa0804525
10.1158/1078-0432.CCR-07-0523
10.1056/NEJM199603143341104
10.3322/canjclin.55.2.74
10.1097/00000658-199810000-00005
ContentType Journal Article
Copyright 2011
2015 INIST-CNRS
Copyright © 2011. Published by Elsevier Inc.
Copyright_xml – notice: 2011
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011. Published by Elsevier Inc.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.transproceed.2011.09.043
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2623
EndPage 3818
ExternalDocumentID 10_1016_j_transproceed_2011_09_043
22172852
25344251
S0041134511012620
1_s2_0_S0041134511012620
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Ohio
GeographicLocations_xml – name: Ohio
GroupedDBID -
08R
0R
1
1-
123
1B1
1P
1~.
1~5
29Q
3O-
4.4
457
4G.
53G
55
5RE
5VS
7-5
71M
8P
AABNK
AACTN
AAEDT
AAIAV
AAIKJ
AAKOC
AALMO
AALRI
AAOAW
AAPBV
AAQFI
AAQXK
AAXUO
ABBQC
ABFLS
ABFRF
ABLJU
ABLVK
ABMAC
ABMZM
ABOCM
ABPIF
ABPTK
ABQIS
ABWYI
ABXDB
ABYKQ
ACDAQ
ACGFO
ACIUM
ACRLP
ADALY
ADBBV
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AFCTW
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FO
G-
G-Q
GBLVA
GJ
HVGLF
HZ
IHE
IPNFZ
J1W
J5H
K
K-O
KOM
L7B
LCYCR
M
M41
MO0
N9A
O-L
O9-
OAUVE
OK-
OW-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
UDS
WH7
X7M
XPP
Y6R
Z5R
ZA5
ZGI
ZXP
---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1P~
8P~
AAEDW
ABJNI
ADMUD
AHPSJ
AXJTR
EFLBG
FYGXN
HZ~
~G-
AAUGY
IQODW
AAXKI
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c464t-3f35b432d50c848d5594171c4cb5a040dc355c632cccea9b378fd9df6a9b20873
IEDL.DBID .~1
ISSN 0041-1345
IngestDate Fri Aug 16 07:46:21 EDT 2024
Thu Sep 26 18:56:58 EDT 2024
Sat Sep 28 08:02:12 EDT 2024
Sun Oct 22 16:04:48 EDT 2023
Fri Feb 23 02:36:10 EST 2024
Thu Aug 18 17:13:44 EDT 2022
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Human
Relapse
Digestive system
Liver
Rate
Prediction
Hepatic disease
Hepatocellular carcinoma
Patient
Malignant tumor
Homotransplantation
Medicine
Liver cancer
Treatment
Tumor growth
Criterion
Surgery
Digestive diseases
Graft
Predictive factor
Cancer
Liver transplantation
Language English
License CC BY 4.0
Copyright © 2011. Published by Elsevier Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c464t-3f35b432d50c848d5594171c4cb5a040dc355c632cccea9b378fd9df6a9b20873
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 22172852
PQID 911950125
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_911950125
crossref_primary_10_1016_j_transproceed_2011_09_043
pubmed_primary_22172852
pascalfrancis_primary_25344251
elsevier_sciencedirect_doi_10_1016_j_transproceed_2011_09_043
elsevier_clinicalkeyesjournals_1_s2_0_S0041134511012620
PublicationCentury 2000
PublicationDate 2011-12-01
PublicationDateYYYYMMDD 2011-12-01
PublicationDate_xml – month: 12
  year: 2011
  text: 2011-12-01
  day: 01
PublicationDecade 2010
PublicationPlace Amsterdam
PublicationPlace_xml – name: Amsterdam
– name: United States
PublicationTitle Transplantation proceedings
PublicationTitleAlternate Transplant Proc
PublicationYear 2011
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References El-Serag, Mason (bib3) 1999; 340
Klintmalm (bib9) 1998; 228
Lee, Heo, Libbrecht (bib13) 2006; 12
Sotiropoulos, Malago, Molmenti (bib15) 2005; 79
Bruix, Sherman (bib5) 2005; 42
Macaron, Hanouneh, Lopez (bib17) 2010; 42
Parkin, Bray, Ferlay, Pisani (bib1) 2005; 55
Hoshida, Villanueva, Kobayashi (bib11) 2008; 359
Freeman, Mithoefer, Ruthazer (bib16) 2006; 6
Lovet, Burroughs, Bruix (bib4) 2003; 362
Jiang, Gusev, Aderca (bib12) 2008; 14
Yao, Bass, Nikolai (bib7) 2002; 8
Mazzaferro, Regalia, Doci (bib6) 1996; 334
Bruix, Sherman (bib14) 2005; 42
Toso, Trotter, Wei (bib8) 2008; 14
Jonas, Bechstein, Steinmüller (bib10) 2001; 33
El-Serag, Rudolph (bib2) 2007; 132
Jiang (10.1016/j.transproceed.2011.09.043_bib12) 2008; 14
Bruix (10.1016/j.transproceed.2011.09.043_bib14) 2005; 42
Lovet (10.1016/j.transproceed.2011.09.043_bib4) 2003; 362
Parkin (10.1016/j.transproceed.2011.09.043_bib1) 2005; 55
Klintmalm (10.1016/j.transproceed.2011.09.043_bib9) 1998; 228
El-Serag (10.1016/j.transproceed.2011.09.043_bib2) 2007; 132
Yao (10.1016/j.transproceed.2011.09.043_bib7) 2002; 8
Bruix (10.1016/j.transproceed.2011.09.043_bib5) 2005; 42
Freeman (10.1016/j.transproceed.2011.09.043_bib16) 2006; 6
Toso (10.1016/j.transproceed.2011.09.043_bib8) 2008; 14
Macaron (10.1016/j.transproceed.2011.09.043_bib17) 2010; 42
Lee (10.1016/j.transproceed.2011.09.043_bib13) 2006; 12
Sotiropoulos (10.1016/j.transproceed.2011.09.043_bib15) 2005; 79
Hoshida (10.1016/j.transproceed.2011.09.043_bib11) 2008; 359
Jonas (10.1016/j.transproceed.2011.09.043_bib10) 2001; 33
El-Serag (10.1016/j.transproceed.2011.09.043_bib3) 1999; 340
Mazzaferro (10.1016/j.transproceed.2011.09.043_bib6) 1996; 334
References_xml – volume: 42
  start-page: 1208
  year: 2005
  ident: bib14
  article-title: Management of hepatocellular carcinoma
  publication-title: Hepatology
  contributor:
    fullname: Sherman
– volume: 42
  start-page: 4585
  year: 2010
  ident: bib17
  article-title: Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria
  publication-title: Transplant Proc
  contributor:
    fullname: Lopez
– volume: 55
  start-page: 74
  year: 2005
  ident: bib1
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
  contributor:
    fullname: Pisani
– volume: 79
  start-page: 483
  year: 2005
  ident: bib15
  article-title: Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?
  publication-title: Transplantation
  contributor:
    fullname: Molmenti
– volume: 8
  start-page: 873
  year: 2002
  ident: bib7
  article-title: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list
  publication-title: Liver Transpl
  contributor:
    fullname: Nikolai
– volume: 14
  start-page: 1107
  year: 2008
  ident: bib8
  article-title: Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma
  publication-title: Liver Transpl
  contributor:
    fullname: Wei
– volume: 14
  start-page: 419
  year: 2008
  ident: bib12
  article-title: Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival
  publication-title: Clin Cancer Res
  contributor:
    fullname: Aderca
– volume: 6
  start-page: 350
  year: 2006
  ident: bib16
  article-title: Staging of hepatocellular cancer (HCC) before liver transplantation is suboptimal
  publication-title: Am J Transplant
  contributor:
    fullname: Ruthazer
– volume: 132
  start-page: 2557
  year: 2007
  ident: bib2
  article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis
  publication-title: Gastroenterology
  contributor:
    fullname: Rudolph
– volume: 42
  start-page: 1208
  year: 2005
  ident: bib5
  article-title: Management of hepatocellular carcinoma
  publication-title: Hepatology
  contributor:
    fullname: Sherman
– volume: 33
  start-page: 1080
  year: 2001
  ident: bib10
  article-title: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis
  publication-title: Hepatology
  contributor:
    fullname: Steinmüller
– volume: 359
  start-page: 1995
  year: 2008
  ident: bib11
  article-title: Gene expression in fixed tissues and outcome in hepatocellular carcinoma
  publication-title: N Engl J Med
  contributor:
    fullname: Kobayashi
– volume: 12
  start-page: 410
  year: 2006
  ident: bib13
  article-title: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
  publication-title: Nat Med
  contributor:
    fullname: Libbrecht
– volume: 362
  start-page: 1907
  year: 2003
  ident: bib4
  article-title: Hepatocellularcarcinoma
  publication-title: Lancet
  contributor:
    fullname: Bruix
– volume: 228
  start-page: 479
  year: 1998
  ident: bib9
  article-title: Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome
  publication-title: Ann Surg
  contributor:
    fullname: Klintmalm
– volume: 334
  start-page: 693
  year: 1996
  ident: bib6
  article-title: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
  publication-title: N Engl J Med
  contributor:
    fullname: Doci
– volume: 340
  start-page: 745
  year: 1999
  ident: bib3
  article-title: Rising incidence of hepatocellular carcinoma in the United States
  publication-title: N Engl J Med
  contributor:
    fullname: Mason
– volume: 132
  start-page: 2557
  year: 2007
  ident: 10.1016/j.transproceed.2011.09.043_bib2
  article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2007.04.061
  contributor:
    fullname: El-Serag
– volume: 8
  start-page: 873
  year: 2002
  ident: 10.1016/j.transproceed.2011.09.043_bib7
  article-title: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list
  publication-title: Liver Transpl
  doi: 10.1053/jlts.2002.34923
  contributor:
    fullname: Yao
– volume: 6
  start-page: 350
  issue: Suppl 12
  year: 2006
  ident: 10.1016/j.transproceed.2011.09.043_bib16
  article-title: Staging of hepatocellular cancer (HCC) before liver transplantation is suboptimal
  publication-title: Am J Transplant
  contributor:
    fullname: Freeman
– volume: 42
  start-page: 4585
  year: 2010
  ident: 10.1016/j.transproceed.2011.09.043_bib17
  article-title: Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2010.10.012
  contributor:
    fullname: Macaron
– volume: 14
  start-page: 1107
  year: 2008
  ident: 10.1016/j.transproceed.2011.09.043_bib8
  article-title: Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma
  publication-title: Liver Transpl
  doi: 10.1002/lt.21484
  contributor:
    fullname: Toso
– volume: 79
  start-page: 483
  year: 2005
  ident: 10.1016/j.transproceed.2011.09.043_bib15
  article-title: Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?
  publication-title: Transplantation
  doi: 10.1097/01.TP.0000152801.82734.74
  contributor:
    fullname: Sotiropoulos
– volume: 33
  start-page: 1080
  year: 2001
  ident: 10.1016/j.transproceed.2011.09.043_bib10
  article-title: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis
  publication-title: Hepatology
  doi: 10.1053/jhep.2001.23561
  contributor:
    fullname: Jonas
– volume: 362
  start-page: 1907
  year: 2003
  ident: 10.1016/j.transproceed.2011.09.043_bib4
  article-title: Hepatocellularcarcinoma
  publication-title: Lancet
  contributor:
    fullname: Lovet
– volume: 12
  start-page: 410
  year: 2006
  ident: 10.1016/j.transproceed.2011.09.043_bib13
  article-title: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
  publication-title: Nat Med
  doi: 10.1038/nm1377
  contributor:
    fullname: Lee
– volume: 340
  start-page: 745
  year: 1999
  ident: 10.1016/j.transproceed.2011.09.043_bib3
  article-title: Rising incidence of hepatocellular carcinoma in the United States
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199903113401001
  contributor:
    fullname: El-Serag
– volume: 42
  start-page: 1208
  year: 2005
  ident: 10.1016/j.transproceed.2011.09.043_bib14
  article-title: Management of hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.20933
  contributor:
    fullname: Bruix
– volume: 359
  start-page: 1995
  year: 2008
  ident: 10.1016/j.transproceed.2011.09.043_bib11
  article-title: Gene expression in fixed tissues and outcome in hepatocellular carcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0804525
  contributor:
    fullname: Hoshida
– volume: 14
  start-page: 419
  year: 2008
  ident: 10.1016/j.transproceed.2011.09.043_bib12
  article-title: Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-0523
  contributor:
    fullname: Jiang
– volume: 334
  start-page: 693
  year: 1996
  ident: 10.1016/j.transproceed.2011.09.043_bib6
  article-title: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199603143341104
  contributor:
    fullname: Mazzaferro
– volume: 55
  start-page: 74
  year: 2005
  ident: 10.1016/j.transproceed.2011.09.043_bib1
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.55.2.74
  contributor:
    fullname: Parkin
– volume: 228
  start-page: 479
  year: 1998
  ident: 10.1016/j.transproceed.2011.09.043_bib9
  article-title: Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome
  publication-title: Ann Surg
  doi: 10.1097/00000658-199810000-00005
  contributor:
    fullname: Klintmalm
– volume: 42
  start-page: 1208
  year: 2005
  ident: 10.1016/j.transproceed.2011.09.043_bib5
  article-title: Management of hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.20933
  contributor:
    fullname: Bruix
SSID ssj0004243
Score 2.0938318
Snippet Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these...
It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low...
BACKGROUNDIt is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients...
SourceID proquest
crossref
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 3813
SubjectTerms alpha-Fetoproteins - analysis
Biological and medical sciences
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - surgery
Cell Differentiation
Cell Proliferation
Disease-Free Survival
Female
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Kaplan-Meier Estimate
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Liver Transplantation - adverse effects
Liver, biliary tract, pancreas, portal circulation, spleen
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Ohio
Patient Selection
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
ROC Curve
Severity of Illness Index
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the digestive system
Time Factors
Tissue, organ and graft immunology
Treatment Outcome
Tumor Burden
Tumors
Title Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria
URI https://www.clinicalkey.es/playcontent/1-s2.0-S0041134511012620
https://dx.doi.org/10.1016/j.transproceed.2011.09.043
https://www.ncbi.nlm.nih.gov/pubmed/22172852
https://search.proquest.com/docview/911950125
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEF5CSqFQSpP0obYxcyg5RYm0O5KlQw-uies-EkxqQ26LtJKISy0ZSz740h_QX93ZXclOKIFCb0LSokXz3N1vvmHsfUZu30uziCyNrAkxQJeyEOXGqac8JRJUBkRzeRWOZ_jlJrjZY8OuFkbDKlvfb3268dbtnfP2b54v53Nd44u-LzS_FjnZkOt1O1IwIp0--7WDeSDvkHO-q9_uiEcNxqsxBOI2UrR0nvGZh-KhIPV0mdT06wrb8-LhpNQEp9Fz9qzNKmFgJ37A9vLykB0NSlpRLzZwAgbnaTbQD9njj93VycTyVm9OYborw6pPzYAto_XmiP2-powUqgKm60W1gk-0dG9uYbLShzxNDdd6z95UDep3xhTgmkofCGiEKwx1s6KyWiQw0O3I4ZsGgoDlVP-Z2MKnEuYlTCzDaw22qAYu5_QY6HOz4fcR6JYM2lhesNnoYjocu20TB1dhiI0rChGkKHgWeCrCKKMVDPp9X6FKg4Q8SKYo41Gh4EqpPIlT0Y-KLM6KkK65Rxr0ku2XVZm_ZoB5hEXBeT8VBWKWR3GQBkWii-JRKS4cJjqpyaXl6pAdiO2HvCtrqWUtvViSrB3W7wQsu2pU8p953RpzLX1Zc-nJvxTOYR-2I-_prKRw9E9f7t3Tp-2keSCQfKnvMOgUTJLVa8klZV6taxmb9r2UnDrslVW83WDTcizgb_5zdm_ZE7N_bqA779h-s1rnx5SANWnPWFiPPRp8_jq--gOpqDIZ
link.rule.ids 315,786,790,4521,24144,27957,27958,45620,45714
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5VRQgkhKDlYR5lDqinurV3x4594BAiQoCkikoi9bay17YIInYUO4dc-AH8amZ37YQKVULiZtleeeV57u433zD2NiO376VZRJZG1oQYoEtZiHLj1FOeEgkqA6KZXIajOX6-Dq4P2KCrhdGwytb3W59uvHV756L9mxerxULX-KLvC82vRU425LRuv6PTed2_4fznHueBvIPO-a5-vWMeNSCvxjCI21DR8nnG5x6K26LUg1VS078rbNOL27NSE52Gj9jDNq2Evp35Y3aQl0fsuF_Sknq5hVMwQE-zg37E7r7vrk6nlrh6ewazfR1WfWYG7Citt8fs1xWlpFAVMNssqzV8pLV78w2ma33K09RwpTftTdmgfmdEEa6p9ImAhrjCQHcrKqtlAn3djxzGGgkCllT9R2Irn0pYlDC1FK812KoamCzoMdDn5oOvQ9A9GbS1PGHz4YfZYOS2XRxchSE2rihEkKLgWeCpCKOMljDo93yFKg0SciGZopRHhYIrpfIkTkUvKrI4K0K65h6p0FN2WFZl_pwB5hEWBee9VBSIWR7FQRoUia6KR6W4cJjopCZXlqxDdii27_JPWUsta-nFkmTtsF4nYNmVo5IDzevWmmvpy5pLT_6lcQ57txt5Q2klxaN_-vLJDX3aTZoHAsmZ-g6DTsEkmb2WXFLm1aaWsenfS9mpw55ZxdsPNj3HAv7iP2f3ht0bzSZjOf50-eUlu2820w2O5xU7bNab_DVlY016YqztN2XrM6s
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rate+of+Tumor+Growth+Predicts+Recurrence+of+Hepatocellular+Carcinoma+After+Liver+Transplantation+in+Patients+Beyond+Milan+or+UCSF+Criteria&rft.jtitle=Transplantation+proceedings&rft.au=Hanouneh%2C+I.A.&rft.au=Macaron%2C+C.&rft.au=Lopez%2C+R.&rft.au=Aucejo%2C+F.&rft.date=2011-12-01&rft.pub=Elsevier+Inc&rft.issn=0041-1345&rft.eissn=1873-2623&rft.volume=43&rft.issue=10&rft.spage=3813&rft.epage=3818&rft_id=info:doi/10.1016%2Fj.transproceed.2011.09.043&rft.externalDocID=S0041134511012620
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00411345%2FS0041134511X0012X%2Fcov150h.gif